CMS To Help Build National FDG-PET Cancer Registry, Will Cover Trials
This article was originally published in The Gray Sheet
Executive Summary
CMS plans to work with stakeholders to develop a national registry as well as small studies to determine the clinical utility of FDG-PET in the management of brain, ovarian, pancreatic and small-cell lung cancers
You may also be interested in...
Informed Consent Issues Proving Tricky In CMS Evidence-Development Policy
Issues surrounding informed consent appear to be complicating CMS' efforts to finalize a policy allowing it to require evidence collection as a condition of national Medicare coverage
Informed Consent Issues Proving Tricky In CMS Evidence-Development Policy
Issues surrounding informed consent appear to be complicating CMS' efforts to finalize a policy allowing it to require evidence collection as a condition of national Medicare coverage
McClellan Expounds On Medicare National Coverage Registry Requirements
The Institute of Medicine is facilitating CMS and industry dialogue on postmarket data collection requirements for national coverage decisions